Catherine Skari
-
Jul- 2024 -4 July
Pociredir
Update: 18 October 2026 No update available. Update: 30 June 2026 Company has announced discontinuation due to FDA concerns…
Read More » -
4 July
Osivelotor
Update: 18 October 2026 No update available. Update: 30 June 2026 • Data presented at the EHA Annual Congress…
Read More » -
2 JulyScientific Literature
Predicting Factors of Survival Rates Among α-and β-Thalassemia Patients: A Retrospective 10-Year Data Analysis
Background: Thalassemia is a genetic hemoglobinopathy in which a defective globin chain can cause transfusion-dependent anemia and other complications. As genotype…
Read More » -
Jun- 2024 -23 JuneNews
CAD | Enjaymo Not Cost-Effective at Current Price, According to US Study
This conclusion was drawn from a cost-effectiveness study utilizing data from the Phase 3 CARDINAL clinical trial, which backed the…
Read More » -
17 JuneNews
SPOTLIGHT | TIF Wins Prestigious HemaSphere Award at EHA2024
The HemaSphere Awards were presented by the official journal of the European Hematology Association (EHA) during Europe’s most important scientific…
Read More » -
16 JuneNews
NEW PUBLICATION | Nutrition in Thalassaemia: A Guide for Patients, Families, and Caregivers
The guide encompasses: An overview of the nutritional needs specific to people with thalassaemia Methods for nutritional assessment Detailed explanations…
Read More » -
3 June
-
2 JuneNews
TIF STUDY | Patient and Caregiver Perceptions of Thalassaemia Care
The study revealed that most patients with thalassaemia are receiving adequate treatment, including regular blood transfusions, chelation therapy, proper monitoring,…
Read More » -
May- 2024 -22 MayNews
WHA77 SIDE EVENT | Access to Novel Therapies Globally: Opportunities and Challenges
The Side Event entitled “Access to Novel Therapies Globally: Opportunities and Challenges” is set to take place Friday, 31 May…
Read More » -
20 May
